Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||TCR alpha/beta+/CD19+ depleted hematopoietic cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TCR alpha/beta+/CD19+ depleted hematopoietic cells||TCR alpha/beta+/CD19+ depleted HPCs||TCR alpha/beta/CD19-depleted HPCs||TCR alpha/beta+/CD19+ depleted hematopoietic cells is a preparation of donor hematopoietic progenitor cells that have been treated to remove the CD19 and TCRalpha/beta-expressing populations, potentially resulting in decreased graft vs. host disease after transplantation (PMID: 27811849, PMID: 29431621).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03849651||Phase II||TCR alpha/beta+/CD19+ depleted hematopoietic cells CD45RA-depleted donor lymphocytes anti-thymocyte globulin + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Thiotepa Blinatumomab||TCRalphabeta-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies||Recruiting|